Why Scientists Are Revisiting a Polarizer - Scorecard - MDSpire

Why Scientists Are Revisiting a Polarizer

The nation’s top cancer institute takes a closer look at a disputed drug.

  • By

  • Rachana Pradhan

  • February 10, 2026

  • 8 min

Share

Clinical Scorecard: Why Scientists Are Revisiting a Polarizer

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationCancer patients, particularly those influenced by misinformation and social media narratives.
Care Setting

Key Highlights

  • NCI is studying ivermectin as a potential cancer treatment despite lack of evidence and new data.

Guideline-Based Recommendations

Diagnosis

    Management

    • Monitor patients for misinformation regarding ivermectin's efficacy.
    • Discourage the use of ivermectin for cancer treatment due to lack of evidence.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with cancer, particularly those influenced by social media narratives.

        No evidence supports ivermectin's safety or efficacy in treating cancer.

        Clinical Best Practices

        • Educate patients about the lack of evidence for ivermectin in cancer treatment.
        • Encourage patients to adhere to proven cancer therapies.
        • Monitor for adverse effects in patients using ivermectin.
        • Discuss the risks associated with ivermectin use.

        References

        Original Source(s)

        Why Scientists Are Revisiting a Polarizer

        • by Rachana Pradhan

        • February 10, 2026

        Related Content

        “Who’s on Backup?”—Exploring Internal Medicine Residency Backup Coverage Systems: Findings from a National Survey

        Recent COVID-19 Shot Linked to Less Spread

        Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.

        Women Overdue for Cancer Screenings

        More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.